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Abstract
Background: Brucellosis may cause serious infections in healthy individuals living in countries that
are endemic for the infection. However, reports of brucella infections in immunocompromised
hosts are relatively rare.
Case Presentations: Reported here are two patients with acute leukemia who developed
Brucella melitensis bacteremia during their follow up at the Armed Forces Hospital in Riyadh. The
first patient developed B. melitensis bacteremia during the transformation of his myelodysplasia into
acute myeloid leukemia. The second patient developed B. melitensis bacteremia while his acute
lymphoblastic leukemia was under control. Interestingly, he presented with acute cholecystitis
during the brucella sepsis. Both brucella infections were associated with a marked reduction in the
hematological parameters in addition to other complications. The bacteremic episodes were
successfully treated with netilmicin, doxycycline and ciprofloxacin.
Conclusion: Brucellosis can cause systemic infections, complicated bacteremia and serious
morbidity in patients with acute leukemia living in endemic areas. These infections may occur at the
presentation of the leukemia or even when the leukemia is in remission. Nevertheless, the early
diagnosis of brucellosis and the administration of appropriate antimicrobial therapy for sufficient
duration usually improves the outcome in these immunocompromised patients.
Background
In patients with malignant disorders, infections are major
causes of morbidity and mortality. In such patients, the
risk of infection is usually related to the intensity and the
duration of cytotoxic chemotherapy and immunosup-
pressive treatment [1]. The main predisposing factors for
infections in patients with cancer are: uncontrolled malig-
nancy, immunosuppressive and cytotoxic chemotherapy
and immunological deficits that include T-cell depletion
and hypogammaglobulinemia. Several immunological
defects may be present in these patients, thus making
them susceptible to a wide range of opportunistic infec-
tions [1].
Brucellosis, the commonest zoonotic infection world-
wide, can affect healthy individuals and immunocompro-
mised patients living in countries that are endemic for the
infection [2-5]. Two patients with acute leukemia, who
developed B. melitensis bacteremia during their follow up
at the Armed Forces Hospital in Riyadh Saudi Arabia, are
reported and the literature is reviewed.
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Case 1
A 57 year old Iraqi male from Rafha refugee camp was
transferred to Riyadh Armed Forces Hospital (RAFH) with
pancytopenia for further evaluation and management. He
had been experiencing anemic manifestations for two
months but no associated bleeding or fever. Physical
examination revealed pallor, no external lymphadenopa-
thy or palpable abdominal organomegaly and normal car-
diovascular and neurological systems. The complete
blood count (CBC) showed: WBC: 1.7 × 109/L, Hb: 35 g/
L and PLT: 106 × 109/L. The blood film revealed neutro-
penia with dysplastic changes and the bone marrow
biopsy (BMB) showed a hypercellular marrow with dys-
plastic changes involving the three hematopoietic cell
lines. After establishing the diagnosis of myelodysplastic
syndrome (MDS), the patient was given supportive meas-
ures to correct his anemia and he was discharged.
Nine months later, the patient was readmitted with high
fever, rigors and low backache of one week duration. His
physical examination did not reveal any new abnormality.
CBC showed: WBC: 1.6 × 109/L with neutrophils of 0.3,
Hb: 50 g/L and PLT: 12 × 109/L. The renal and the hepatic
profiles were all within normal limits. The blood cultures
grew: B. melitensis sensitive to ciprofloxacin, netilmicin,
and tetracycline but resistant to trimethoprim-sulphame-
thoxazole (TMP/SMZ). The brucella agglutination anti-
body titer was highly elevated (1:20480). A repeat BMB
showed dysplastic changes and 20% myeloblasts, i.e. evi-
dence of transformation into acute myloid leukemia
(AML). For the brucella bacteremia (BB), the patient
received IV netilmicin 5 mg/kg three times per day and
oral doxycycline 200 mg twice daily for one week. A few
days after starting these antibiotics, the fever and the back-
ache subsided. Then netilmicin was replaced by oral cip-
rofloxacin 500 mg twice daily and the patient was
continued on oral doxycycline. After controlling the bru-
cella sepsis, the patient was commenced on an induction
course of chemotherapy composed of daunorubicin 50
mg/day IV for 1 day and cytosine arabinoside 100 mg/m2/
day IV for 5 days. After successful management of both the
BB and the leukemic transformation of MDS, the patient
was discharged on ciprofloxacin and doxycycline for a
total duration of 5 weeks.
Four months later, the patient was readmitted with a new
AML transformation of his MDS and severe bronchopneu-
monia. Cultures of the blood, the sputum and the bron-
choalveolar lavage fluid were all negative. There was no
clinical or microbiological evidence of recurrence of the
brucella infection. However, he received IV netilmicin,
ciprofloxacin and amoxicillin but unfortunately he
responded poorly to the antimicrobials given and despite
receiving full supportive care, he deteriorated further and
died.
Case 2
A 54 year old Saudi male, with history of chronic relapsing
brucellosis for 15 years, was diagnosed to have acute lym-
phoblastic leukemia [ALL] at MD Anderson Cancer Centre
in the USA. He achieved the first complete remission (CR)
of his leukemia after receiving an induction course of
chemotherapy composed of cyclophosphamide, dauno-
rubicin, vincristine, L-asparaginase and intrathecal meth-
otrexate. Three years later, the patient had a central
nervous system (CNS) relapse of his leukemia followed by
a bone marrow relapse which were treated with intrathe-
cal chemotherapy and three courses of systemic chemo-
therapy. Subsequently, the patient achieved the third CR
of his ALL, but he developed a number of complications
including hyperbilirubinemia, generalized pigmentation,
pancreatitis, paralytic ileus and hepatic failure. He also
developed several infections including staphylococcal
bacteremia, Hemophilus influenzae bronchopneumonia
and Campylobacter bacteremia which were all managed
successfully.
Five years after the diagnosis of ALL, the patient was read-
mitted to RAFH with fever for 5 days and abdominal pain
of one week duration. Physical examination revealed an
unwell middle aged male, generalized pigmentation, a
tinge of jaundice, no palpable lymph nodes, a clear chest
and normal cardiovascular and neurological systems. The
abdomen was distended with tenderness in the epigas-
trium and the right hypochodrium. The liver and spleen
were impalpable, the bowel sounds were positive and
there was no ascites. CBC showed: WBC: 2.1 × 109/L (neu-
trophils: 1.04), Hb: 113 g/L and PLT: 22 × 109/L and the
blood film showed no blast cells. The BMB showed a
hypocellular marrow with no evidence of leukemia. An
abdominal ultrasound showed an acutely inflamed and
distended gall bladder. Blood cultures grew B. melitensis,
sensitive to ciprofloxacin, netilmicin and doxycycline. The
brucella agglutination antibody titer was elevated [total
1:2560, IgG 1:640, IgM 1:10240]. The acute cholecystitis
was managed conservatively with bowel rest, IV fluids and
analgesics. The BB was treated with IV netilmicin 15 mg/
kg/day in three divided doses and oral doxycycline 200
mg twice daily for 3 weeks and then the IV netilmicin was
replaced by oral ciprofloxacin 500 mg twice daily. After
controlling the acute cholecystitis and the BB, the patient
was discharged on oral ciprofloxacin and doxycycline for
three more weeks. Thereafter the patient had regular fol-
low up at the hematology outpatient clinic and no further
recurrence of his brucellosis has been encountered.Page 2 of 4
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Brucella species are small Gram-negative, aerobic and
non-motile intracellular coccobacilli that can be isolated
from the genitourinary tracts of many wild and domestic
animals [2]. The human pathogens: Brucella abortus (B.
abortus), B. suis, B. canis and B. melitensis can cause sys-
temic infections which may affect any body organ [2,6-8].
Over the past decade, the epidemiology of human brucel-
losis has drastically changed due to a number of sanitary,
socioeconomic and political reasons [3]. Several tradi-
tionally endemic areas including France and several coun-
tries in Latin American have achieved control of the
disease while new foci have emerged in Asia and in the
Near East [3]. Unfortunately, the disease is still present in
varying trends in some European countries and in the USA
[3]. Brucellosis is transmitted to humans by direct contact
with infected animals or ingestion of unpasteurized milk
and dairy products [2,9]. The occupational exposure of
abattoir workers, veterinarians and laboratory technicians
can result in transmission of the disease through contam-
inated aerosols [2]. Transmission of the infection by
blood transfusion is possible but very unusual [9].
The clinical manifestations of brucellosis and BB are vari-
able and may include fever, rigors, anorexia, malaise,
weight loss, backache, bony pains, arthritis and arthralgias
and hepatosplenomegaly [2,4-8,10-13]. Brucellosis has
been reported to cause acute abdominal conditions such
as cholecystitis, appendicitis and pancreatitis [14]. In such
conditions, abdominal ultrasound is helpful in establish-
ing the diagnosis and the management includes not only
antimicrobial therapy for brucellosis but also specific
therapy for the acute abdomen that may involve surgical
intervention [14].
Brucellosis may cause a wide range of hematological
abnormalities including anemia, leucopenia, thrombocy-
topenia, pancytopenia, bleeding diathesis and dissemi-
nated intravascular coagulation (DIC) [6,8,10-12]. Up to
87.5% of patients with pancytopenia induced by brucella
infection have positive blood cultures for the organism
and almost 100% of these patients have positive brucella
serology [2,6,7]. Almost all the changes in the hematolog-
ical parameters encountered in patients with brucellosis
are transient and reversible provided an appropriate anti-
microbial therapy is rapidly instituted [6,11,12]. The bone
marrow changes seen in patients with brucellosis are var-
iable and may include: hypercellular or nomocellular
marrows, hemophagocytosis and granulomatous changes
[6,10-13].
BB develops in 38 to 90% of patients infected with bru-
cella and most of the patients with BB have positive bru-
cella serology [2,7]. BB may be complicated by: infective
endocarditis, fatal endotoxic shock that may be associated
with DIC, multiorgan failure, microangiopathic hemo-
lytic anemia with bleeding tendency and pancytopenia
and death [7,8,13]. Despite the severity of these complica-
tions, the early use of appropriate antimicrobial therapy
usually leads not only to clinical improvement but also to
normalization of the hematological parameters and the
coagulation profile [7,8,13].
Although a presumptive diagnosis of brucellosis can be
made by demonstrating high or rising antibody titers to
brucella antigen, the isolation of the organism from
blood, bone marrow or tissue cultures provides the only
definitive evidence of the infection [2]. Because of the
suboptimal recovery rate of brucellae from the blood, cul-
tures of the bone marrow, liver or lymph nodes may
improve the recovery rate of the organism [2]. The use of
aerobic bottles of the automated continuous-monitoring
blood culture system eg BACTEC 9000 makes possible the
diagnosis in more than 95% of positive blood cultures
within 7 days [2]. The brucella ELISA test is a rapid test
that can be performed easily and it can also be automated.
It is a reliable and a sensitive test in the diagnosis of bru-
cellosis [15].
Different antibiotic regimens have been employed in the
treatment of brucellosis including the following in vari-
ous combinations: TMP/SMZ, rifampicin, doxycycline,
ciprofloxacin, gentamicin and streptomycin [4,7,8,13].
The mean duration of treatment is usually 6 weeks, but in
case of complications like infective endocarditis or spinal
involvement, therapy may be prolonged for up to 3
months [7]. The in-vitro resistance to TMP/SMZ is rather
high, approximately 29%, but the overall rate of clinical
relapse is rather low, about 5% [7].
Brucellosis is one of the leading infections causing pyrexia
of unknown origin (PUO) in some parts of the world [4].
In patients with febrile neutropenia who are unresponsive
to empirical antibiotic therapy, brucellosis may lead to
treatment failure due to the late appearance of signs and
symptoms and because of its slow growth in blood cul-
tures [4]. On a few occasions, brucellosis has been
encountered in patients with acute leukemia and solid
tumors [4,5]. As reported cases of brucellosis developed in
patients with malignant disorders living in countries that
are endemic for this infection, the dominant presenting
features of brucellosis were febrile neutropenia and pan-
cytopenia [4,5]. The first patient presented in this case
report developed BB when his primary disease (MDS) was
transforming into AML. His blood counts were decreasing
further and he presented with severe pancytopenia and
the classical features of brucellosis. However, he
responded very well to the treatment given, his clinical
status improved and his blood indices increased signifi-
cantly after the control of the brucella sepsis, whichPage 3 of 4
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allowed the administration of cytotoxic chemotherapy to
control his acute leukemia. The second patient had a reac-
tivation of an old brucella infection following the sup-
pression of immunity after receiving repeated courses of
cytotoxic chemotherapy to control relapsing ALL. How-
ever, this patient developed BB, which was associated with
severe pancytopenia, whilst his ALL was under control
and simultaneously he presented with clinical and ultra-
sonic evidence of acute cholecystitis causing an acute
abdomen. Both the BB and the acute abdomen were man-
aged successfully despite his age, his poor general condi-
tion and the poor prognosis of his primary hematological
disorder. Interestingly, both patients had strongly positive
brucella serology.
In comparison with the few reported cases of acute leuke-
mia and brucellosis, our patients demonstrated the fol-
lowing peculiar features: (1) The development of BB not
only at the presentation of leukemia but also when leuke-
mia was in remission. (2) The profound reduction in
blood indices caused by the BB was reversible once an
appropriate therapy had been administered. (3) Despite
their depressed immunity, both patients were able to
mount rather brisk immunologic responses to the BB
reflected by the greatly elevated agglutination antibody
titers.
Conclusion
Brucella infection should always be included in the differ-
ential diagnosis of febrile neutropenia, pancytopenia and
even acute abdomen in immunocompromised hosts liv-
ing in geographic areas that are endemic for brucellosis.
Specific investigations including blood cultures for bru-
cella and brucella serology should be taken and appropri-
ate antimicrobial therapy should be initiated promptly.
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